This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

OPKO Commences Pivotal Clinical Validation Study For 4Kscore™ As A Predictor Of Prostate Cancer Prior To Biopsy

OPKO Health, Inc. (NYSE: OPK) has commenced a pivotal, multi-center clinical validation study for the Company’s proprietary 4Kscore™ test for the prediction of prostate cancer prior to prostate biopsy. The 4Kscore™ test is based on over a decade of research of a four kallikrein panel of biomarkers conducted by scientists at Memorial Sloan Kettering Cancer Center and leading research centers in Europe on over 10,000 patients. The OPKO multi-center study is expected to generate data to support the launch of the 4Kscore™ test as a laboratory developed test through the Company’s CLIA laboratory in Nashville, TN. The Company has begun enrolling patients at the first of 13 sites across the United States and is planning to enroll more than 1,200 patients referred for a prostate biopsy over the course of the next few months.

“The OPKO Lab 4Kscore™ test is expected to be an important tool in the fight against prostate cancer and the prevention of unnecessary biopsies,” said Dr. Peter Scardino, Chair, Department of Surgery, Memorial Sloan Kettering Cancer Center. “We are optimistic that the newly initiated clinical study will prospectively demonstrate for U.S.-based clinicians and payers the value of the 4Kscore™ test as an important guide in managing patients.”

According to a paper titled “The Kallikrein Panel for Prostate Cancer Screening: Its Economic Impact”, published online October 26, 2013 in the journal The Prostate, it is estimated that about $1 billion in healthcare costs could be saved annually in the U.S. by implementing a four kallikrein panel test and using the results of the test to determine if a prostate biopsy should be performed.

“We believe OPKO’s 4Kscore™ test will address a significant unmet medical need for better tests to identify men at risk for aggressive prostate cancer, while at the same time avoiding unnecessary, costly, and potentially harmful treatments,” said Phillip Frost, M.D., OPKO's Chairman and Chief Executive Officer.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs